Amgen Inc. $AMGN Shares Sold by SVB Wealth LLC

SVB Wealth LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 40.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,959 shares of the medical research company’s stock after selling 3,356 shares during the period. SVB Wealth LLC’s holdings in Amgen were worth $1,745,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AMGN. Robeco Institutional Asset Management B.V. grew its position in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after buying an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC purchased a new stake in shares of Amgen in the fourth quarter valued at about $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Amgen during the fourth quarter worth about $22,441,000. Finally, Sigma Planning Corp increased its stake in shares of Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after acquiring an additional 3,488 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 0.7%

Shares of NASDAQ AMGN opened at $347.01 on Wednesday. The firm’s 50-day moving average is $340.42 and its two-hundred day moving average is $345.87. The company has a market capitalization of $187.28 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42. Amgen Inc. has a 12-month low of $269.01 and a 12-month high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the company posted $4.90 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AMGN shares. Mizuho lifted their price objective on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. UBS Group raised their price target on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Argus decreased their price target on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Canaccord Genuity Group initiated coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective on the stock. Finally, Daiwa Securities Group cut their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $354.42.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.